Wall Street Analysts Think Corcept (CORT) Could Surge 41.31%: Read This Before Placing a BetZacks Investment Research • 10/01/24
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price ForecastBenzinga • 09/30/24
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT)PRNewsWire • 08/26/24
Wall Street Analysts Believe Corcept (CORT) Could Rally 70.58%: Here's is How to TradeZacks Investment Research • 08/16/24
Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?Zacks Investment Research • 08/01/24
Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great ChoiceZacks Investment Research • 07/31/24
Wall Street Analysts See a 37.6% Upside in Corcept (CORT): Can the Stock Really Move This High?Zacks Investment Research • 07/31/24
Corcept Therapeutics: Q2 Gains Overshadowed By Generic Competition And Speculative PipelineSeeking Alpha • 07/30/24
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat EstimatesZacks Investment Research • 07/29/24
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024InvestorPlace • 06/26/24
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association's Scientific SessionsGlobeNewsWire • 06/24/24
Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?Zacks Investment Research • 06/14/24